Final Program

392 WEDNESDAY • MAY 18
12:15 Update on Current Pulmonary Issues at the FDA
L.I. Gilbert-McClain, MD, Silver Spring, MD
12:33 Old Drug New Use: Anticholinergics and Asthma
S.J. Chin, MD, Silver Spring, MD
12:51 Targeted Therapy for Asthma: Lessons from the IL-5 Pathway
K.M. Donohue, MD, Silver Spring, MD
1:09 Questions and Answers
L.I. Gilbert-McClain, MD, Silver Spring, MD
L24
VARIOUS ORGANIZATIONS
RESEARCH FUNDING OPPORTUNITIES
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Room 2001/2003 (West Building, Level 2)
Target Audience
Any ATS member who conducts research and is seeking funding.
Objectives
At the conclusion of this session, the participant will be able to:
• describe the research priorities of each funding agency represented on the
panel;
• discuss practical steps that researchers take to improve quality of grant
applications;
• identify a funding agency that is most closely aligned with the attendee’s
research interests.
This session will introduce programs and research grant opportunities offered
from major funding agencies. Speakers will present current research priorities
and mechanisms of research funding available from each agency.
Chairing: J. Yorke, PhD, RN, Manchester, United Kingdom
J. Choi, PhD, RN, Pittsburgh, PA
12:15 National Institute of Nursing Research
N. Redeker, PhD, RN, West Haven, CT
12:25 National Heart, Lung, and Blood Institute
L. Reineck, MD, Bethesda, MD
12:35 Department of Veterans Affairs
E.G. Collins, PhD, RN, Chicago, IL
12:45 American Lung Association
S. Rappaport, MPH, New York, NY
12:55 ATS Program of Research
Speaker To Be Announced
1:05 Panel Discussion
J. Yorke, PhD, RN, Manchester, United Kingdom
L25
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH
NEW RESULTS FROM THE COPDGENE STUDY
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Target Audience
Those with clinical or research responsibilities.
Room 2002/2004 (West Building, Level 2)
Objectives
At the conclusion of this session, the participant will be able to:
• learn about imaging in the COPDGene study;
• understand and learn about subtypes identified by the COPDGene study;
• learn about longitudinal follow-up in the COPDGene study.
Chronic obstructive pulmonary disease (COPD), the third leading cause of
death in the United States, is a heterologous syndrome. The COPDGene study
has created the largest cohort of well-characterized current and former smokers
for respiratory disease research. The primary goals of COPDGene are: 1) to
identify new genetic loci that influence the development of COPD and
COPD-related phenotypes and 2) to reclassify COPD into subtypes that can
ultimately be used to develop effective therapies. This session will describe the
progress and future plans of the COPDGene study.
Chairing: E.K. Silverman, MD, PhD, Boston, MA
J.D. Crapo, MD, Denver, CO
L. Postow, PhD, Bethesda, MD
12:15 Overview of COPDGene
J.D. Crapo, MD, Denver, CO
12:27 Longitudinal Follow-Up of COPDGene Subjects: Clinical
Epidemiology
M.K. Han, MD, MS, Ann Arbor, MI
12:39 Advances in Quantitative Lung Imaging and Visual CT
Assessment
D.A. Lynch, MD, Denver, CO
12:51 COPD Genetics: From GWAS to Sequencing
E.K. Silverman, MD, PhD, Boston, MA
1:03 Defining Subtypes of COPD
M.H. Cho, MD, MPH, Boston, MA
L26
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH
ENHANCED PHENOTYPING OF PULMONARY
VASCULAR DISEASES
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Target Audience
Health providers, trainees, and researchers.
Room 2006/2008 (West Building, Level 2)
ATS 2016 • San Francisco